Carotid IMT was determined at study entry and the end of the trial. The intent-to-treat analysis included 56 subjects in the acarbose and 59 in the control group who had a baseline and endpoint measurement. RESULTS: A significant reduction of the progression of IMT(mean) was observed in the acarbose group versus placebo. 